b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia

British Journal of Haematology

Volumn 109, Issue 3, 2000, Pages 616-621

  Norbury, Louise C ^a   Clark, Richard E ^a   Christmas, Stephen E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Cytotoxic T lymphocytes; Immunotherapy

Indexed keywords

BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; HLA A3 ANTIGEN; HLA B8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; PHYTOHEMAGGLUTININ;

ANTIGEN PRESENTING CELL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIGEN-PRESENTING CELLS; CELLS, CULTURED; FUSION PROTEINS, BCR-ABL; HLA-A3 ANTIGEN; HLA-B8 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-7; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034044688     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02090.x     Document Type: Article

References (35)

1. Barrett, J., Guimaraes, A., Cullis, J. & Goldman, J.M. (1993) Immunological characterisation of the tumour specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukaemia. Stem Cells, 11, 104-108.
2. Bocchia, M., Wentworth, P.A., Southwood, S., Sidney, J., McGraw, K., Scheinberg, D.A. & Sette, A. (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood, 85, 2680-2684.
3. Bocchia, M., Korontsvit, T., Xu, Q., MacKinnon, S., Yang, S.Y., Sette, A. & Scheinberg, D.A. (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood, 87, 3587-3592.
4. Buzyn, A., Ostankovitch, M., Zerbib, A., Kemula, M., Connan, F., Varet, B., Guillet, J.G. & Choppin, J. (1997) Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. European Journal of Immunology, 27, 2066-2072.
5. Champlin, R. (1995) Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Experimental Hematology, 23, 1148-1151.
6. Choudhury, A., Gajewski, J.L., Liang, J.C., Popat, U., Claxton, D.F., Kliche, K.-O., Andreeff, M. & Champlin, R.E. (1997) Use of leukaemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukaemia. Blood, 89, 1133-1142.
7. Coulie, P.G. & van Pel, A. (1993) Defined antigens recognized by T lymphocytes on human tumours. Current Opinion in Oncology, 5, 1043-1048.
8. Datta, A.R., Barrett, A.J., Jiang, Y.Z., Guimaraes, A., Mavroudis, O.A., van Rhee, F., Gordon, A.A. & Madrigal, A. (1994) Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplantation, 14, 517-524.
9. Dermime, S., Mavroudis, D., Jiang, Y.-Z., Hensel, N., Molldrem, J. & Barrett, A.J. (1997) Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplantation, 19, 989-999.
10. Evavold, B.D., Sloan-Lancaster, J. & Allen, P.M. (1993) Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunology Today, 14, 602-609.
11. Greco, G., Fruci, D., Accapezzato, D., Barnaba, V., Nisini, R., Alimena, G., Montefusco, E., Vingneti, E., Butler, R., Tanigaki, N. & Tosi, R. (1996) Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of cytotoxic T lymphocytes. Leukemia, 10, 693-699.
12. Herman, J., van der Bruggen, P., Luescher, I.F., Mandruzzato, S., Romero, P., Thonnard, J., Fleischhauer, K., Boon, T. & Coulie, P.G. (1996) A peptide encoded by the human MAGE3 gene and presented hy HLA-B44 induces cytotytic T-lymphocytes that recognise tumour cells expressing MAGE3. Immunogenetics, 43, 377-383.
13. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. British Journal of Haematology, 93, 606-612.
14. Kersh, G.J. & Allen, P.M. (1996) Essential flexibility in the T cell recognition of antigen. Nature, 380, 495-498.
15. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Areese, W., Ljungman, P., Ferrant, A., Verdonck I., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, F. & Ansari, H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
16. Kurzrock, R., Guttermann, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome-positive leukaemias. New England Journal of Medicine, 319, 990-998.
17. MacIntyre, A.R., Christmas, S.E. & Clark, R.E. (1996) The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Experimental Hematology, 24, 1307-1311.
18. + T lymphocytes respond to dendritic cells pulsed with b 3a2 peptide and antigen-presenting cells exposed to b 3a2 containing cell lysates. Blood, 90, 290-297.
19. Marrack, P. & Parker, D.C. (1994) A little of what you fancy.... Nature, 368, 397-398.
20. Momigliano Richiardi, P., Tosi, R., Martinelli, G., Saglio, G., Conte, R., Barbanti, M., Dall'Omo, A., Farabegoli, P., Favoino, B., Gambelunghe, C., Gandini, A.R., Marceno, R., Misefari, V., Mulargia, M., Pratico. L. & Zaccaria, A. (1994) The HLA class I-CML association revisited taking into account the two forms of gene fusion in the Philadelphia chromosome. A multicenter study. Leukemia, 8, 2134-2137.
21. Nanda, N.K. & Sercarz, E.E. (1995) Induction of anti-self immunity to cure cancer. Cell, 82, 13-17.
22. Nieda, M, Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Takadoro, K. & Juji, T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukaemic cells from patients with chronic myeloid leukaemia. Blood, 91, 977-983.
23. Papadopoulos, K.P., Suciu-Foca, N., Hesdorffer, C.S., Tugulea, S., Maffei, A. & Harris, P.E. (1997) Naturally processed tissue and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukaemia blasts. Blood, 90, 4938-4946.
24. Pawelec, G., Max, H., Halder, T., Breserud, O., Merl, A., da Silva, P. & Kalbacher, H. (1996) BCR/ABL leukaemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognised by T cells found at low frequency in the repertoire of normal donors. Blood, 88, 2118-2124.
25. Plebanski, M., Allsopp, C.E., Aidoo, M., Reyburn, H. & Hill, A.V. (1995) Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. European Journal of Immunology, 25, 1783-1787.
26. Posthuma, E.F.M., Falkenburg, J.H.F., Apperley, J.F., Gratwohl, A., Schipper, R.F., Schreuder, G.M.T., D'Amaro, J., Biezen, J.H.V., Hermans, J., Willemze, R. & Niederwieser, D. (1998) HLA-DR4 and HLA-DR15 lower the risk of the acquisition of chronic myeloid leukaemia. British Journal of Haematology, 102, 284.
27. Posthuma, E.F.M., Falkenburg, J.H.E., Apperley, J.F., Gratwohl, A., Roosnek, F., Hertenstein, B., Schipper, R.F., Schreuder, G.M.T., D'Amaro, J., Oudshoorn, M., van Biezen, J.H., Hermans, J., Willemze, R. & Niederwieser, D. (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia. Blood, 93, 3863-3865.
28. Rock, K.L. (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunology Today 17, 131-137.
29. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwartz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H. & White, D.E. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 4, 321-327.
30. Smit, W.M., Rijnbeek, M., van Bergen, C.A.M., Willemze, R. & Falkenburg, J.H.F. (1998) Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukaemia using modifications of a limiting dilution assay. Bone Marrow Transplantation, 21, 553-560.
31. Sorensen, P.H. & Triche, T.J. (1996) Gene fusions encoding chimaeric transcription factors in solid tumours. Seminars in Cancer Biology, 7, 3-14.
32. BCR ABL protein by human T cells. Leukemia, 9, 1344-1348.
33. ten Bosch, G.J.A., Joosten, A.M., Kessler, J.H., Melief, C.J.M. & Leeksma, O.C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood, 88, 3522-3527.
34. + cytotoxic T-cell clones specific for bcr-abl b 3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b 3a2-specific and HLA-DR restricted manner. Blood, 92, 3355-3361.
35. Yotnda, P., Firat, P., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J.P., Lemonnier, F.A., Leblond, V. & Langlade-Demoyen, P. (1998) Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. Journal of Clinical Investigation, 101, 2290-2296.